HDAC6-Selective Inhibitor Overcomes Bortezomib Resistance in Multiple Myeloma

Although multiple myeloma (MM) patients benefit from standard bortezomib (BTZ) chemotherapy, they develop drug resistance, resulting in relapse. We investigated whether histone deacetylase 6 (HDAC6) inhibitor A452 overcomes bortezomib resistance in MM. We show that HDAC6-selective inhibitor A452 sig...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Sang Wu, Yeon, Soo-Keun, Kim, Go Woon, Lee, Dong Hoon, Jeon, Yu Hyun, Yoo, Jung, Kim, So Yeon, Kwon, So Hee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7866276/
https://www.ncbi.nlm.nih.gov/pubmed/33572814
http://dx.doi.org/10.3390/ijms22031341

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7866276/
https://www.ncbi.nlm.nih.gov/pubmed/33572814
http://dx.doi.org/10.3390/ijms22031341

Ejemplares similares